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Objective. Cardiovascular disease is associated with inﬂammation and immune activation, concentrations of immune activation
markers like neopterin predict outcome in adults. Methods. Serum neopterin concentrations and early metabolic and pre-
atherosclerotic symptoms were analyzed in 295 obese juveniles and 101 normal weight controls of similar age. Additionally, the
inﬂuence of a 12 months weight reduction program on neopterin levels was investigated in 31 obese juveniles. Results.I n t i m a -
media thickness of common carotid arteries (IMT) and the concentrations of C-reactive protein (CRP) were increased in the
obese juveniles (P<. 001). Also triglycerides, oxidized LDL, fasted insulin levels, HOMA-index, leptin, liver transaminases and
uricacidwereincreasedcomparedtothecontrols.However,serumneopterinwasdecreasedintheobeseversusnon-obesejuveniles
(P<. 03). The intervention consisting of regular sports, nutritional devices, and a psychologic attendance led after 12 months to
an increase of neopterin concentration (P<. 05; paired test). Conclusions. Neopterin concentrations in juvenile obesity behaved
considerably diﬀerent from what was demonstrated in adults, levels did not correlate with metabolic and pre-atherosclerotic
symptoms found in early phases although early vascular burden and chronic low grade inﬂammation was indicated by increased
IMT and CRP. Neopterin concentrations increased after a 12 months intervention program.
1.Introduction
Nowadays, the role of inﬂammation and immune activation
in atherogenesis is well established [1], and the activation
of macrophages appears to be of critical relevance within
this process [1, 2]. Cardiovascular disease (CVD) is also
associated with increased neopterin concentrations [3–10],
and predictive information is provided by neopterin in
patients at risk of myocardial infarction [11–16]. A recent
study in 2312 patients undergoing angiography demon-
strated that neopterin is an independent predictor of total
and cardiovascular mortality [17]. Likewise, in patients with
diabetes, both neopterin and C-reactive protein (CRP) were
independent predictors of fatal ischemic heart disease [18].
Neopterin is produced by human monocyte-derived
macrophages and dendritic cells preferentially upon stimu-
lation with Th1-type cytokine interferon-γ (IFN-γ)[ 19, 20].
Thus, neopterin concentrations reﬂect activation of the Th1-
type immune response [21]. In humans, increased neopterin
concentrations are detected in patients with virus infections
including human immunodeﬁciency virus, infections by
intracellular bacteria and parasites, autoimmune diseases,
malignant tumors, and during rejection episodes in allograft
recipients [21–24].
In foregoing studies, we detected an increased carotid
intima-media thickness (IMT) indicating preatherosclerosis
paralleled by a subclinical inﬂammation in obese juveniles
aged around 13 years [25]. Additionally, we showed an
inﬂuenceofsubcutaneousadipose tissuetopographyontotal
adiponectin and adiponectin subfraction serum levels in
obese juveniles and provided the ﬁrst evidence that incipient
atherosclerosis yet found in adolescents by an increased IMT
is associated with a disturbed oligomerisation from low-
molecular to high-molecular-weight adiponectin [26, 27].2 Journal of Obesity
In a group of otherwise healthy adults, a positive
correlation was observed between neopterin concentrations
and body mass index [28]. From the data obtained in adults,
it appears that neopterin serum levels are associated with
chronic subclinical inﬂammation and preatherosclerotic
symptoms in early phases of obesity in a particular manner.
In this study, we analysed serum concentrations of neopterin
with carotid IMT, and cardiovascular risk factors in a cohort
of 295 obese juveniles and adolescents compared to 101
normal weighted, healthy controls of the same age and
gender distribution. Further, we investigated the inﬂuence
of a weight reduction program performed for 12 months
in a subgroup of 40 obese juveniles on neopterin serum
concentrations.
2.Materialsand Methods
2.1. Patients. Study participants were from the STYrian
Juvenile Obesity Study (STYJOBS), which is designed to
investigate early stages of atherosclerosis and metabolic
disorders in obese juveniles. STYJOBS is registered at
http://clinicaltrials.gov/ (Identiﬁer NCT00482924), where
detailed information of the study is available. The inclu-
sion criterium for the obese probands was body mass
index (BMI) > 97th percentile if under 18 years of age,
BMI > 30kg/m2 if over 18 years of age. Exclusion criteria
were endocrine diseases (e.g., hypothyroidism), infectious,
inﬂammatory, or any other chronic diseases. Controls were
healthy juvenile volunteers recruited from the Department
of Pediatric Surgery, where they underwent minor elective
surgery (e.g., herniotomia). Fasted blood samples were
collected prior to anaesthesia and surgery. All controls had
to be normal weight, free of infectious, and endocrine or any
other diseases. 295 juveniles (mean age 12.9 ± 3.3 SD years)
and 101 normal weight healthy controls of similar age and
gender distribution were investigated.
Out of this cohort, 40 juveniles with BMI > 97th per-
centile (male 17, female 23, mean age 13.6 + 2.3 years (SD))
underwenta12-monthweightreductionprogramduringthe
year 2006. The intervention schedule encompassed regular
sports (2 times per week, one hour, 12 months), nutritional
devices (1x/week, 1st three months, 1x/2 weeks, 2nd three
months, 1x/4 weeks within the remaining 6 months),
and a psychologic attendance. Thirtyone obese juveniles
(male 13, female 18) who fully completed this program were
included in the analysis of the neopterin kinetics during
intervention.
The study was approved by the Ethical Committee of
the Medical University of Graz. Blood collection and ultra-
sonography were performed after written informed consent
w a sg i v e nb yt h ep r o b a n d si fa g e do v e r1 8y e a r s ,o rb yt h e i r
parents, if they were under 18 years old. At the time of blood
collection, the probands were fasting. Venous puncture was
performed in a standard procedure (cubital vein approach
with butterﬂy); blood samples were immediately centrifuged
at 3500rpm at ambient temperature and stored at −80◦C
until analysis.
2.2. Carotid Artery Ultrasound. The ultrasound protocol
involved scanning of the bulbous near the common carotid
artery on both sides with a 12-to-5-MHz broad-band linear
transducer on an HDI 5000 (ATL, Bothell, Washington, DC,
USA). All scans were performed by the same investigator.
Longitudinalimagesdirectedthroughthecenteroftheartery
were taken at each vessel site. Measurements were made
from stored digital images by an experienced reader. The
carotid IMT was assessed at the far wall as the distance
between the interface of the lumen and intima, and the
interface between the media and adventitia. The maximal
IMT was recorded at each of the vessel segments and
averaged for the left and right sides. The lumen diameter was
calculated as the interadventitial diameter minus twice the
maximum far wall IMT. All diameters were measured during
diastole to avoid image blurring due to systolic arterial wall
motion and to minimize the inﬂuence of blood pressure
[29].
2.3. Lipometry. Measurements of total percentual body fat
were performed as described elsewhere by means of a
lipometer, a patented optical device (EU Pat.Nr. 0516251)
[30].
2.4. Laboratory Analysis. Neopterin concentrations were de-
termined by enzyme-linked immunosorbant assay (ELISA)
( B R A H M SD i a g n o s t i c a ,H e n n i g s d o r f ,G e r m a n y ) .T o t a l
adiponectin, leptin, and resistin were determined by ELISA
(BiovendorLaboratoryMedicineInc.,Brno,CzechRepublic)
according to manufacturer’s instructions. Intra- and interas-
say coeﬃcients of variation for all ELISAs in our study
were below 10 percent. Cholesterol and triglycerides were
measured by means of ECLIA (Electro Chemi Luminiscence
Assay) on an Elecsys 2010 analyser (Roche Diagnostics
Mannheim, Germany), and lipoproteins were separated by
a combined ultracentrifugation-precipitation method (β-
quantiﬁcation). Blood lipids inclusive of fatty acids were
analysed as outlined elsewhere [31]. Oxidized low-dense
lipoprotein (oxLDL) was measured by a commercially avail-
able ELISA(Mercodia oxidized LDL Competitive ELISA,754
50 Uppsala, Sweden). Concentrations of CRP were analysed
with a highly sensitive particle-enhanced immunoturbidi-
metric assay (Tina-quant C-reactive protein latex ultrasensi-
tive assay, Roche diagnostics). Plasma insulin was measured
by ELISA (Mercodia, Uppsala, Sweden) and plasma glucose
was measured by the glucose hexokinase method on a
Hitachi 917 chemical analyser. HOMA-IR (homeostatic
model assessment-insulin resistance) was calculated as the
product of the fasting plasma insulin value (in μU/ml)
and the fasting plasma glucose value (mm/L), divided
by 22.5 [27]. Liver transaminases AST/GOT, ALT/GPT, γ-
GT, creatinine, and uric acid were measured by routine
laboratory methods on a Hitachi 917 chemical analyser.
2.5. Statistic Analysis. Statistical analysis was performed by
SPSS version 14. Kolmogorov-Smirnov test was used to
examine for normal distribution. Means were compared by
a two-tailed unpaired sample t-test or by Mann-WhitneyJournal of Obesity 3
Test, depending on the distribution of the data. A value
of P<. 05 was considered statistically signiﬁcant. Least
squares regression analysis was performed to test the corre-
lation between variables according to Pearson. Signiﬁcance
of correlation was determined by univariate ANOVA and
subsequent multiple comparison analysis. Bonferroni cor-
rection was used for multiple comparisons after ANOVA.
To exclude a dependence of the resulting correlations from
other variables, the correlations were adjusted by partial cor-
relations. Stepwise multiple regression analysis was applied
to investigate correlations between neopterin as dependent
variable and diﬀerent metabolic and vascular measures as
independent variables.
3.Results
The clinical and laboratory characteristics of the study
probands are summarized in Table 1.O b e s ej u v e n i l e sh a d
a signiﬁcantly increased IMT (P<. 001) and elevated
CRP, (P<. 001, see also Figure 1) indicating early
stages of atherosclerosis and chronic low-grade inﬂam-
mation (Table 1). Oxidized LDL, fasted insulin, HOMA-
index, resistin, and systolic-, diastolic-blood pressure were
signiﬁcantly increased, and HDL cholesterol signiﬁcantly
decreased in the obese cohort (Table 1). Compared to the
controls, obese juveniles had signiﬁcantly lower neopterin
serum concentrations (Table 1 and Figure 1). Neopterin
concentrations did not correlate with percentual body fat
or BMI-SDS values in the whole study cohort and were
independent from any other variable investigated in this
study and listed in Table 1 (data not shown).
After the 12-month weight reduction program con-
sisting of regular sports, nutritional devices, and a psy-
chologic attendance, the total percentual total body fat,
oxLDL, and resistin serum concentrations decreased signif-
icantly whereas the HDL-cholesterol levels were signiﬁcantly
increased (Table 2). CRP concentrations increased upon
intervention as compared with baseline, but the diﬀerence
was not signiﬁcant. Fasted blood glucose, insulin levels, IMT
of common carotid arteries, and systolic and diastolic blood
pressure did not diﬀer signiﬁcantly from baseline (details
not shown). After the 12-month intervention program,
neopterin concentrations increased and the mean value
became higher than baseline (Table 2). This increase of
neopterin concentrations did not correlate with the decrease
of the BMI-SDS.
4.Discussion
Our study shows that serum neopterin concentrations are
not increased in obese adolescents compared to nonobese
controls, rather a trend to subnormal levels was observed.
Although neopterin concentrations were lowered only by
approximately 10% compared to the nonobese controls, the
diﬀerence was signiﬁcant. This result is astonishing com-
pared to results obtained in several studies performed earlier
by various research groups in adults: adults with high risk
for atherosclerosis presented with slightly but signiﬁcantly
Obese Nonobese
P<. 05
0
3
6
9
N
e
o
p
t
e
r
i
n
(
n
m
o
l
/
L
)
(a)
Obese Nonobese
P<. 001
0
2
4
6
C
-
r
e
a
c
t
i
v
e
p
r
o
t
e
i
n
(
m
g
/
d
L
)
(b)
Figure 1: Serum concentrations of neopterin and C-reactive pro-
tein in obese and nonobese adolescents. Neopterin concentrations
are given as mean values (boxes) and S.E.M. (bars) and because
of nonnormal distribution C-reactive protein is given as medians
(boxes) and 25–75th percentiles (bars).
increased serum neopterin concentrations compared to low-
risk persons [11–18, 32]. Myocardial infarction (MI) is
usually accompanied by a transient increase of neopterin
[33]. Although only moderately elevated compared to other
clinical conditions like acute virus infections or cancer,
neopterin levels showed a predictive potential for future
clinical events in symptomatic and stable CVD patients
[12, 15, 17, 18, 34]. This predictive value of neopterin was
found to be independent from other biomarkers such as
CRP [16–18, 32] .T h ea b i l i t yt oe n h a n c eo x i d a t i v es t r e s s
and to induce proinﬂammatory cytokine cascades [33,
35] via induction of nuclear factor κB suggests neopterin4 Journal of Obesity
Table 1: Characteristics of the study subjects.
Variable Controls (n = 101) Obese adolescents (n = 295)
Age (Years) 12.9 ± 2.7 (4–18) 12.4 ± 2.9 (4–18)
Body Length (m) 1.56 ± 0.14 1.56 ± 0.14
Body Weight (kg) 47.2 ± 13.4 74.5 ± 24.2∗∗
BMI (kg/m2) 18.7 (16.9–20.4) 28.9 (26.2–32.4)+++
BMI-SDS 0.21 (−0.7–0.8) 5.4 (4.0–7.2)+++
Carotid IMT (cm) 0.052 ± 0.009 0.070 ± 0.09∗∗∗
Neopterin (nmol/L) 5.3 ± 1.9 4.9 ± 1.8∗
C-Reactive protein (mg/dl) 0.26 (0.17–0.84) 1.9 (0.9–3.8)+++
HDL-cholesterol (mg/dl) 48.4 ± 12.0 41.9 ± 11.2∗∗∗
Oxidized LDL (mg/dl) 35.1 ± 15.3 44.3 ± 16.9∗∗∗
Insulin (uE/ml) 7.9 (5.1–12.7) 15.4 (8.8–29.1)+++
HOMA-IR 1.7 (1.0–2.7) 3.5 (1.8–6.9)+++
Resistin (ng/ml) 3.7 ± 1.5 4.3 ± 1.6∗∗
SBP (mmHg) 115 ± 4.9 125 ± 15.5∗∗∗
DBP (mmHg) 63.1 ± 96 8 ± 8.8∗∗∗
Resultsare expressedas mean ± S.D. analysedby Student’st-test (∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 001) or as median (25th–75th percentile) and Mann Whitney
U test (+P<. 05, ++P<. 01, +++P<. 001) depending on the distributionof data.
BMI, body mass index; BMI-SDS, BMI-standard deviation score; HOMA-IR, homeostatic model assessment-insulinresistance; SBP, systolic blood pressure;
DBP, diastolic blood pressure; carotid IMT, carotid intima-media thickness.
Table 2: Neopterin, body fat, HDL cholesterol, resistin, oxLDL, and C-reactive protein concentrations (mean ± S.D.) before and after 12
months of intervention therapy.
Start of intervention End of intervention (12 months)
n 31 (male 13, female 18) 31
Neopterin (nmol/L) 4.4 ± 0.38 5.0 ± 1.7∗
Body fat (%) 36.8 ± 7.0 29.5 ± 5.1∗∗∗
HDL cholesterol (mg/dl) 42.4 ± 7.6 47.2 ± 9.3∗
Resistin (ng/ml) 4.7 ± 1.6 3.9 ± 0.9∗
Oxidized LDL (mg/dl) 59.7 ± 10.8 53.1 ± 16.3∗
C-reactive protein (mg/dl) 2.8 ± 2.6 3.2 ± 3.2
∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 001 (paired t-test).
to act as a proinﬂammatory biomarker in atherogenesis
[36]. Neopterin appears to play an important role in the
pathogenesis of CVD. However, to our surprise this seems
to be true only in adults but not in juvenile obesity. There is
already information available from adults that CAD activity
more than the size of lesions is important for the elevation
ofneopterin, butin contrast, despite detectable CADactivity
in juvenile obesity, neopterin concentrations tended to even
lower levels than in nonobese controls of similar age.
Increased neopterin concentrations are characteristic for
an activated Th1-type immune response [22]. Accordingly,
the decreased or low-neopterin concentrations found in
our study cohort of obese adolescents even if rather
small in absolute terms might indicate a suppressed Th1-
type immunity and thus lowered IFN-γ production [37].
In fact, only the neopterin concentrations found in the
obese groups were lower than normal, the mean value of
neopterin concentrations measured in the nonobese control
population (5.3 ± 1.9nmol/L; Table 1) was almost identical
with the one found in larger populations of adult blood
donors and healthy controls as 5.3 ± 2.7nmol/L [21, 22,
38]. At present, increased neopterin concentrations are well
established in patients with several diseases which are known
to be associated with immune activation such as virus infec-
tions, autoimmune syndromes, and various types of cancer
[21, 22]. However, subnormal or suppressed neopterin
release in clinical disease is rather rare. Only from in vitro
studies, it is known that several antioxidant compounds
are able to slowdown neopterin production in peripheral
blood mononuclear cells. Among them are antioxidant food
supplements like preservatives and colorants, but also high
dose of antioxidant vitamins C and E suppresses Th1-type
cytokinesand induceesa Th2-type immunity patternin vitro
[39].
Whereas antioxidant compounds were observed to sup-
press Th1-type immunity and neopterin production in
vitro, physical exercise and sports like long-distance running
and hiking were found to induce a transient increase of
neopterin concentrations [40, 41]. An increase of neopterin
concentrations was also observed in a rather small subgroupJournal of Obesity 5
of our patients who attended an intervention therapy
during one year that comprised improved dietary habits
and the increase of exercise. This increase of neopterin
indicates a proinﬂammatory response which is induced by
exercise and corresponds nicely to the above-mentioned
earlier ﬁndings in healthy individuals. Thus, the most
direct and consistent interpretation would be that physi-
cal exercise was responsible for the increase of neopterin
concentrations.
One may concludethatlow or evensubnormal neopterin
concentrations may relate to a low incidence of physical
activities in obese juveniles. Moreover, in diabetes patients,
antioxidants have been recently found to prevent the health-
promoting eﬀects of physical exercise [42]. In conclusion,
low frequency of physical exercise and sports as well as
antioxidant food supplements could contribute to the low
neopterin levels in obese juveniles, and it may contribute
to weight gain. However, this is merely speculation and still
the increase of body weight and the decrease of neopterin
might well develop in parallel and are not necessarily linked
directly.
Unfortunately, the ﬁndings of the intervention program
appearsomewhathamperedbythefactthatthoseindividuals
who were willing to enter this program presented with
baseline levels somewhat diﬀerent from the whole study
group, for example, neopterin concentrations were slightly
lower and resistin and CRP levels were slightly but not
signiﬁcantly higher. The intervention program increased
neopterin concentrations, but the average neopterin level
reached was only slightly higher as compared to the whole
groupwithoutanyspecialsportsactivities. Stillthediﬀerence
of neopterin concentrations before and after intervention
was signiﬁcant when paired samples of the subgroup were
compared. Certainly a larger study will be necessary to
adequately address this issue, but it is not easy to get.
According to the ﬁndings on neopterin concentrations,
obesity in adolescents might be classiﬁed as a condition
linked with Th2-type immunity. It will be interesting to
investigate in future whether the balance between Th1- and
Th2-type immunity is essentially involved in the observed
neopterin kinetics and in obesity development. It can be
speculated that the early low-grade inﬂammation, as found
in our obese juveniles in context with an already increased
IMT, may be a more Th2-driven process, whereas the
advanced atherosclerosis of adulthood is associated with
a stronger Th1-type immune activation. There might be
a role of mast cells which are known to be strongly
engaged in the allergic response but also have the potential
to promote atherosclerosis by releasing proinﬂammatory
cytokines which could become relevant with older age [43].
In conclusion, the ﬁnding of low-serum neopterin con-
centrations in obese juveniles forces one to consider that
the pathogenesis of cardiovascular disease development in
childrenandjuvenilesmaydiﬀerfromadults.Furtherstudies
should help to better deﬁne age-dependent diﬀerences and
to deﬁne optimized preventive strategies, not only the
increase of physical exercise and sports but also avoidance of
antioxidant food supplements such as preservatives or extra
vitamins might be of beneﬁt.
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